我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
37
5 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
已完成
22
59.5%
尚未招募
5
13.5%
招募中
10
27.0%
暂无批准数据
- Towa Pharmaceutical and Kyoto University have initiated the final phase of a clinical trial testing bromocriptine, a Parkinson's drug, as a potential treatment for familial Alzheimer's disease using innovative iPS drug discovery methods. - The trial, running until March 2028, will enroll 24 patients with familial Alzheimer's disease caused by specific gene mutations, with preliminary results showing no disease-specific side effects and potential suppression of cognitive decline. - This represents a novel approach to treating early-onset familial Alzheimer's disease, a rare form affecting individuals under 60, for which no cure currently exists despite available symptomatic treatments.
